Opioid Use Disorder: Conference Sessions

MGH 50th Annual Psychopharmacology Conference

October 16–18, 2026 · Boston, MA

• LectureAlcohol and Opioids

  Vinod Rao

  Pharmacotherapy for alcohol and opioid use disorders.

  Alcohol Use Disorder

AACAP Annual Meeting 2026

October 26–31, 2026 · Atlanta, GA

• WorkshopBuprenorphine 2.0: Prescribing Buprenorphine to Adolescents With Opioid Use Disorder

  Brady J. Heward · Paul E. A. Glaser · Jesse Hinckley · Sivabalaji Kaliamurthy

  Case-based workshop on prescribing buprenorphine to adolescents and young adults with opioid use disorder, covering consent, initiation, titration, discontinuation and comorbidity management.

  Child & AdolescentSubstance Use Disorders

• PosterOptimizing Naloxone Prescription at Saint Louis Children’s Hospital in At-Risk Pediatric Patients

  Brandon Trojanowski · Stephen E. Irwin · Michael L. Wenzinger · Annie Chang

  Quality improvement project aimed at improving naloxone prescribing for at-risk pediatric patients at a children's hospital.

  Child & Adolescent

• PosterMental Health History and Perioperative Opioid Outcomes in Adolescents: A Propensity-Matched Cohort Analysis

  Anjali Pathak · Abhinav Singh Verma · Parth Modi · Vasudha Sharma · Pragya Tiwari · Richa Raina · Raman Marwaha

  Propensity-matched cohort poster on how adolescents' mental health history relates to opioid outcomes after surgery.

  Child & AdolescentMedical Comorbidity & C-L Psychiatry

APNA 40th Annual Conference

October 28–31, 2026 · Phoenix, AZ

• LectureMedetomidine in the Fentanyl Era: Emergence of a Veterinary Sedative as a Novel Adulterant

  Deborah Salani · Beatriz Valdes · Deana Goldin

  Overview of medetomidine appearing as an adulterant in the fentanyl supply, its potency, and implications for overdose management. Pharmacology-eligible.

  Drug Interactions & SafetySubstance Use Disorders

• WorkshopFinding Balance: Stabilization Through MOUD

  Kayla Cross

  Covers combining buprenorphine-based medication for opioid use disorder with harm-reduction approaches to stabilize patients. Pharmacology-eligible.

• WorkshopRethinking Risk: Harm Reduction as Essential Psychiatric Nursing Practice

  Kayla Cross

  Positions harm reduction as core nursing practice, drawing on a year-long collaborative program serving high-risk communities.

  Substance Use Disorders

• LectureEvaluating the Efficacy of a Standardized Buprenorphine Induction Protocol to Reduce Precipitated Withdrawal in Emergency Department Patients with Opioid Withdrawal

  Marcus Boutte

  Evidence for standardized ED buprenorphine induction protocols that lower precipitated-withdrawal risk and improve engagement.

  Emergency & Acute Psychiatry

• LectureBuprenorphine in the Fentanyl Era: Emerging Evidence and Experiences From the Front Lines

  Mark Crawford · Kevin Paschall

  Low-barrier buprenorphine strategies adapted to how fentanyl has changed opioid use disorder treatment. Pharmacology-eligible.

AAAP 37th Annual Meeting and Scientific Symposium

November 12–15, 2026 · Memphis, TN

• WorkshopImproving Emergency Department Protocols of Care for Overdose Survivors Using Suicide Prevention Frameworks

  Joan Chen · Amira Athanasios · Jessica Sainz

  Adapts suicide prevention frameworks to strengthen emergency department care pathways for overdose survivors.

  Emergency & Acute PsychiatrySuicide & Self-Harm

• WorkshopThe Vagus Nerve and Neurostimulation for Opioid Use Disorder and Chronic Pain

  Zev Schuman-Olivier · Alta DeRoo

  Explores vagus nerve stimulation and related neurostimulation approaches for opioid use disorder and chronic pain.

  Neuromodulation (ECT, TMS)

• Oral abstractMedications for Opioid Use Disorder in VHA Acute Care Settings: A Quality Improvement Study

  Brian Fuehrlein

  Quality improvement study of MOUD delivery in VHA acute care settings.

  Emergency & Acute Psychiatry

• Oral abstractNearcasting the Overdose Crisis: Key Insights from US Drug Dynamics

  Joseph Friedman

  Presents near-real-time modeling of US overdose and drug supply trends.

  Substance Use Disorders

• Oral abstractThe Overdose Crisis is Not Over: Race, Age, and Sex Disparities in Opioid-Related Acute Care, 2016–2023

  Tiffany Xie

  Analyzes racial, age and sex disparities in opioid-related acute care use.

  Diverse & Underserved Populations

See all 48 opioid use disorder sessions at this meeting →

Substance Use Disorders: A Comprehensive Review and Update 2027

February 15–17, 2027 · Lake Buena Vista, FL

• LectureMethadone

  Laura G. Kehoe

  Reviews methadone treatment for opioid use disorder.

• LecturePain

  Jessica Gray

  Addresses pain management in patients with addiction.

  Substance Use Disorders

• LectureBuprenorphine 101

  Jessica Gray

  Introduction to buprenorphine treatment for opioid use disorder.

• LectureLong-Acting Injectable Buprenorphine

  Laura G. Kehoe

  Covers long-acting injectable buprenorphine formulations.

  Long-Acting Injectables

• LectureNaltrexone Intramuscular

  Laura G. Kehoe

  Discusses intramuscular naltrexone in treatment.

  Long-Acting Injectables

Psych Congress 2026

September 15–19, 2026 · New Orleans, LA

• DebateSolving Clinical Challenges: Curbside Solutions for Complex Substance Use Disorder Cases

  Arwen Podesta · Veronica Ridpath · Lydia Bartholow

  Case-based panel dissecting complex opioid, stimulant, and withdrawal scenarios — including where system failures and clinical errors led to poor outcomes — with harm-reduction takeaways.

  Emergency & Acute PsychiatrySubstance Use Disorders

• SymposiumDifficult Medicines: Understanding the Opioid Treatment Landscape for Safe and Effective Outcomes

  Elizabeth Langmore-Avila · Arwen Podesta

  Compares methadone, buprenorphine, and naltrexone for opioid use disorder, covering patient selection, titration, cardiac and overdose considerations, sedative co-prescribing, and transitions between agents.

  Benzodiazepines & SedativesDrug Interactions & Safety